Sonrotoclax
- Generic Name
- Sonrotoclax
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
Phase 1
Active, not recruiting
- Conditions
- Mature B-Cell Malignancies
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 437
- Registration Number
- NCT04277637
- Locations
- 🇺🇸
UCLA Hematologyoncology, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation
Phase 2
Recruiting
- Conditions
- Richter Transformation
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 83
- Registration Number
- NCT04271956
- Locations
- 🇦🇹
Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇪Charité Berlin, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath